For pharmaceutical and biotech companies, rare diseases present huge market opportunities — but also, potentially daunting development challenges.
To advance a gene or cell therapy product into clinical trials, drug developers must first gain a thorough understanding of how the agent travels through the body and to the target (or off-target) organs. Beyond this, qPCR can be used to evaluate vector shedding of gene therapies in body fluids and excreta, and provide a basis for which to evaluate transgene expression in the presence of vector.
Lovelace Biomedical’s scientific team will share two recent examples of their advanced preclinical work in defining animal models for radiation research at the upcoming Radiation Research Society’s annual meeting, Oct. 15-18 in Cancun, Mexico.
It was nearly a century ago, in 1918, that an influenza pandemic swept the world, killing as many as 40 million people. The “Spanish Flu,” as it was known, ended up causing nearly 675,000 deaths in the U.S., as it was a strain that quickly converted to pneumonia at a time when antibiotic drugs weren’t available.
Get an inside look into a 15-year collaboration between the scientists at Lovelace Biomedical and engineers at Capsugel, a company that develops and manufactures dosage forms for the biopharmaceutical and consumer health industries.
The race is on for better therapies to treat pulmonary fibrosis, a chronic lung disease characterized by irreversible scarring of lung tissue. Though the condition is classified as a rare disease, its impact on patients is profound: nearly as many Americans die each year from the most common form of the disease, idiopathic pulmonary fibrosis (IPF), as from breast cancer.